Page last updated: 2024-11-06

butoprozine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Butoprozine is a synthetic anticholinergic compound with a chemical structure similar to benztropine. It is a muscarinic acetylcholine receptor antagonist, meaning it blocks the action of acetylcholine at these receptors. Butoprozine has been investigated for its potential therapeutic effects in various conditions, including Parkinson's disease, Alzheimer's disease, and dystonia. However, its use has been limited due to its adverse effects, such as dry mouth, blurred vision, and constipation. The exact mechanism of action of butoprozine in these conditions is not fully understood, but it is thought to involve its ability to reduce cholinergic hyperactivity in the brain. Research on butoprozine has been ongoing for several decades, and its potential applications are still being explored. Its synthesis involves a multi-step process starting from readily available starting materials. The compound has been studied for its effects on different brain regions and its potential to alleviate symptoms associated with neurological disorders.'
```

butoprozine: benzoylindolizine derivative related to amiodarone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71959
CHEMBL ID2110811
SCHEMBL ID1815972
MeSH IDM0063809

Synonyms (18)

Synonym
methanone, (4-(3-(dibutylamino)propoxy)phenyl)(2-ethyl-3-indolizinyl)-
butoprozinum [inn-latin]
butoprozina [inn-spanish]
butoprozine [inn]
butoprozine
[4-[3-(dibutylamino)propoxy]phenyl]-(2-ethylindolizin-3-yl)methanone
62228-20-0
9xwf3530og ,
butoprozinum
unii-9xwf3530og
butoprozina
methanone, (4-(3-(dibutylamino)-propoxy)phenyl)(2-ethyl-3-indolizinyl)-
p-(3-(dibutylamino)propoxy)phenyl 2-ethyl-3-indolizinyl ketone
SCHEMBL1815972
CHEMBL2110811
Q27273362
(4-(3-(dibutylamino)propoxy)phenyl)(2-ethyl-3-indolizinyl)-methanone
DTXSID20866923

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (93.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.55 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (13.33%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]